Skip to main content

European Headache Federation (EHF) reappraisal of standard of care preventives in migraine

Editor:
Christian Lampl: Konvent Hospital Barmherzige Brüder Linz, Austria

Submission Status: Open   |   Submission Deadline: 1 October 2023


The Journal of Headache and Pain invites participating authors to submit their manuscripts to our Collection on European Headache Federation (EHF) reappraisal of standard of care preventives in migraine.

Migraine is a debilitating disorder leading to a significant burden of affected individuals and high monetary costs. The development of new molecules for migraine prevention has enabled a great leap forward in headache medicine. However, geographical areas that lack access to such therapies cover most migraine patients, although it is indispensable to minimize the risks of progressive worsening of their disease. This disparity to medical care can furthermore be included in the UN Sustainable Development Goal 3 (SGD3) program focused on Health and Population, later taken up by the One Health for Headache Project. This Collections aims to provide robust scientific evidence in favor of individuals living with migraine, especially those with a disadvantage for access to innovative treatments because of socio-cultural, macroeconomic, and national registration reasons.

This Collection supports and amplifies research related to SDG3.

Image credit: © steph photographies / stock.adobe.com (Symbolbild mit Fotomodell)

Meet the Guest Editor

Back to top

Christian Lampl: Konvent Hospital Barmherzige Brüder Linz, Austria

 Prof. Christian Lampl, MD, PhD, is Head of the Department of Neurology at the Konvent Hospital Barmherzige Brüder Linz and the Director of the Headache Medical Center Linz. Prof. Lampl is current President of the European Headache Federation.

The Journal of Headache and Pain invites participating authors to submit their manuscripts to our Collection on European Headache Federation (EHF) reappraisal of standard of care preventives in migraine.

Migraine is a debilitating disorder leading to a significant burden of affected individuals and high monetary costs. The development of new molecules for migraine prevention has enabled a great leap forward in headache medicine. However, geographical areas that lack access to such therapies cover most migraine patients, although it is indispensable to minimize the risks of progressive worsening of their disease.

This disparity to medical care can furthermore be included in the UN Sustainable Development Goal 3 (SGD3) program focused on Health and Population, later taken up by the One Health for Headache Project.

In this perspective, the European Headache Federation proposes a reanalysis of the Standard of Care (SoC) for migraine prevention including drugs that have been approved in other indications than for migraine. The aim is to provide robust scientific evidence in favor of individuals living with migraine, especially those with a disadvantage for access to innovative treatments because of socio-cultural, macroeconomic, and national registration reasons.

This overview will appraise amitriptyline, flunarizine, propranolol, topiramate.

Image credit: © steph photographies / stock.adobe.com (Symbolbild mit Fotomodell)

  1. Topiramate is a repurposed first-line treatment for migraine prophylaxis. The aim of this systematic review and meta-analysis is to critically re-appraise the existing evidence supporting the efficacy and tole...

    Authors: Bianca Raffaelli, David García-Azorín, Deirdre M. Boucherie, Faisal Mohammad Amin, Christina I. Deligianni, Raquel Gil-Gouveia, Sarah Kirsh, Christian Lampl, Simona Sacco, Derya Uluduz, Jan Versijpt, Antoinette MaassenVanDenBrink, Dena Zeraatkar, Margarita Sanchez-del-Rio and Uwe Reuter
    Citation: The Journal of Headache and Pain 2023 24:134
    Content type: Review Published on:

  2. Novel disease-specific and mechanism-based treatments sharing good evidence of efficacy for migraine have been recently marketed. However, reimbursement by insurers depends on treatment failure with classic an...

    Authors: Christina I. Deligianni, Simona Sacco, Esme Ekizoglu, Derya Uluduz, Raquel Gil-Gouveia, Antoinette MaassenVanDenBrink, Raffaele Ornello, Margarita Sanchez-del-Rio, Uwe Reuter, Jan Versijpt, Tessa de Vries, Muizz Hussain, Dena Zeraatkar and Christian Lampl
    Citation: The Journal of Headache and Pain 2023 24:128
    Content type: Review Published on:

  3. The aim of this paper is to critically re-appraise the published trials assessing amitriptyline for migraine prophylaxis.

    Authors: Christian Lampl, Jan Versijpt, Faisal Mohammad Amin, Christina I. Deligianni, Raquel Gil-Gouveia, Tanvir Jassal, Antoinette MaassenVanDenBrink, Raffaele Ornello, Jakob Paungarttner, Margarita Sanchez-del-Rio, Uwe Reuter, Derya Uluduz, Tessa de Vries, Dena Zeraatkar and Simona Sacco
    Citation: The Journal of Headache and Pain 2023 24:39
    Content type: Research Published on:

Submission Guidelines

Back to top

This Collection invites participating authors to submit their manuscripts (reviews and meta-analysis). Before submitting your manuscript, please ensure you have read our submission guidelines. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection, please select European Headache Federation (EHF) reappraisal of standard of care preventives in migraine from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Guest Editors have no competing interests with the submissions which they handle through the peer-review process. The peer-review of any submissions for which the Guest Editors have competing interests is handled by another Editorial Board Member who has no competing interests.